middle.news
Cambium Bio Advances Elate Ocular Phase 3 Trial with FDA Single Pivotal Study Pathway amid AUD 4.1M Loss
5:08pm on Friday 28th of August, 2026 AEST
•
Biotechnology
Read Story
Cambium Bio Advances Elate Ocular Phase 3 Trial with FDA Single Pivotal Study Pathway amid AUD 4.1M Loss
5:08pm on Friday 28th of August, 2026 AEST
Key Points
FDA endorses single pivotal Phase 3 trial for Elate Ocular
FY2026 net loss of AUD 4.1 million on slightly lower royalty revenue
Raised AUD 4.57 million via equity placements at premiums during FY2026
Manufacturing partnerships secured with Locus Cell and ZYBT
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cambium Bio (ASX:CMB)
OPEN ARTICLE